Personal tools
You are here: Home / Events / Seminars / Frontier Leaders: The Intriguing Interaction of Prion Protein with Nucleic Acids and Glycosaminoglycans in Function and Disease

Frontier Leaders: The Intriguing Interaction of Prion Protein with Nucleic Acids and Glycosaminoglycans in Function and Disease

Filed under:

Jerson L. Silva, Universidade Federal do Rio de Janeiro

When 08 Oct, 2010 at 02:30 pm
Where Auditorium
Add event to your calendar iCal

Fronteir Leaders Seminar


Title: The Intriguing Interaction of Prion Protein with Nucleic Acids and Glycosaminoglycans in Function and Disease

Speaker: Jerson L. Silva (cv)

Affiliation: Instituto de Bioquímica Médica, Centro Nacional de Ressonância Magnética Nuclear Jiri Jonas, Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB), Universidade Federal do Rio de Janeiro, Brazil. 
 
Abstract:

The concept that transmissible spongiform encephalopathies (TSEs) are caused only by a protein has changed the traditional paradigm that disease transmission is due solely to an agent that carries genetic information. The main hypothesis for prion diseases proposes that conversion of the cellular prion protein (PrPC) into a misfolded, b-sheet-rich isoform (PrPSc) accounts for the development of (TSE). There is substantial evidence that the infectious material consists chiefly of a protein, PrPSc, with no genomic coding material - unlike a virus particle, which has both. However, prions seem to have other accomplices that chaperone their activity in converting the PrPC into the disease-causing isoform. Among chaperone candidates, nucleic acids (NAs) and glysosaminoglycans (GAGs) are the most likely. The main hypothesis for the mechanism is that cofactor binding reduces the protein mobility and therefore makes the protein-protein interactions more likely (J Biol Chem 2001, 276: 49400-49409; Trends Biochem Sci, 2008, 33: 132-140; J Biol Chem, 2008, 283: 19616-19625). We present our recent studies that show that PrP recognizes many NAs and GAGs with high affinities, and we correlate these findings with a possible pathophysiological role for this interaction. PrP binds NAs both ex vivo and in vitro with sequence and structural selectivity, and some of the PrP:NA complexes can become proteinase K-resistant, undergoing amyloid oligomerization and conversion to a b-sheet-rich structure. These results are consistent with the hypothesis that endogenous polyanions (such as NAs and GAGs) may accelerate the rate of prion disease progression by acting as scaffolds or lattices that mediate the interaction between PrPC and PrPSc molecules. In addition to a still open possibility that NAs (especially from the host) may modulate the conversion, the recent structural characterization of a PrP:NA complex has raised the possibility of developing new diagnostic and therapeutic strategies. Recent studies showing that modified oligonucleotides, as well low-molecular-weight heparin (LMWHep), have potent anti-scrapie activities suggest their therapeutic potential and highlight the importance of obtaining structural information on PrP:NA complexes. 

Document Actions